<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934307</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AGT01-001</org_study_id>
    <secondary_id>2019-000129-39</secondary_id>
    <nct_id>NCT03934307</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ALN-AGT01 in Patients With Hypertension</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Dose and Active Comparator-Controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-AGT01 in Patients With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and&#xD;
      pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 in participants with&#xD;
      hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose&#xD;
      (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in&#xD;
      hypertensive participants with controlled salt intake, Part D will be a MD phase in&#xD;
      hypertensive participants who are obese, and Part E will be an open-label SD phase with&#xD;
      co-administration of irbesartan in hypertensive patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Blood Angiotensinogen (AGT) Level</measure>
    <time_frame>Parts A, B and E: each up to approximately 12 months; Part D: up to approximately 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of ALN-AGT01 and of Potential Metabolites</measure>
    <time_frame>Parts A, B and E: Up to Day 15; Part D: Up to Day 99</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) of ALN-AGT01 and of Potential Metabolites</measure>
    <time_frame>Parts A, B and E: Up to Day 15; Part D: Up to Day 99</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Part A: SAD: ALN-AGT01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of ALN-AGT01.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: SAD: ALN-AGT01-Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be administered a single dose of ALN-AGT01-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: SD: ALN-AGT01</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with controlled salt intake will be administered a single dose of ALN-AGT01.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: SD: ALN-AGT01-Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: Open Label: ALN-AGT01 + Irbesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-AGT01</intervention_name>
    <description>ALN-AGT01 will be administered by subcutaneous (SC) injection.</description>
    <arm_group_label>Part A: SAD: ALN-AGT01</arm_group_label>
    <arm_group_label>Part B: SD: ALN-AGT01</arm_group_label>
    <arm_group_label>Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo</arm_group_label>
    <arm_group_label>Part E: Open Label: ALN-AGT01 + Irbesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-AGT01-Matching Placebo</intervention_name>
    <description>Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.</description>
    <arm_group_label>Part A: SAD: ALN-AGT01-Matching Placebo</arm_group_label>
    <arm_group_label>Part B: SD: ALN-AGT01-Matching Placebo</arm_group_label>
    <arm_group_label>Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Irbesartan will be administered orally.</description>
    <arm_group_label>Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan</arm_group_label>
    <arm_group_label>Part E: Open Label: ALN-AGT01 + Irbesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan-Matching Placebo</intervention_name>
    <description>Irbesartan-matching placebo will be administered orally.</description>
    <arm_group_label>Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has mild to moderate hypertension with mean sitting systolic blood pressure (SBP) of&#xD;
             &gt;130 and ≤165 mmHg without hypertensive medication for Parts A, B and D, and &gt;135 and&#xD;
             ≤165 mmHg without hypertensive medication for Part E&#xD;
&#xD;
          -  Parts A and B: Has body mass index (BMI) ≥18 and ≤35 kg/m^2; Part D: Has BMI &gt;35 and&#xD;
             ≤50 kg/m^2; Part E: Has BMI ≥18 kg/m^2 and ≤50 kg/m^2&#xD;
&#xD;
          -  Has a normal 12-lead electrocardiogram (ECG)&#xD;
&#xD;
          -  Is a nonsmoker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has secondary hypertension&#xD;
&#xD;
          -  Has orthostatic hypotension&#xD;
&#xD;
          -  Has estimated glomerular filtration rate (eGFR) of &lt;60 mL/min/1.73m^2&#xD;
&#xD;
          -  Recently received an investigational agent&#xD;
&#xD;
          -  Has diabetes mellitus&#xD;
&#xD;
          -  Has history of any cardiovascular event&#xD;
&#xD;
          -  Has history of intolerance to SC injection(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

